TY - JOUR AU - Chakra Chaulagain AU - John Ng AU - David Wazer AU - Muhammad Saif PY - 2012/07/10 Y2 - 2024/03/28 TI - Adjuvant Therapy of Pancreatic Cancer JF - JOP. Journal of the Pancreas JA - JOP VL - 13 IS - 4 SE - Highlights from the “2012 ASCO Annual Meeting”. Chicago, IL, USA. June 1-5, 2012 DO - 10.6092/1590-8577/935 UR - http://www.serena.unina.it/index.php/jop/article/view/935 AB - Adjuvant therapy for pancreatic cancer remains controversial. However, both sides of the Atlantic Ocean agree that at least gemcitabine should be the pivotal agent offered to all patients. The role of radiation therapy remains somewhat inconclusive but chemoradiation, whether in the neoadjuvant or adjuvant setting is a standard option often utilized in the USA. This review is an update from the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL, USA. We present the summary of the findings from Abstracts #4020, #4021, #4040 and #4049 and discuss the impact on this group of patients.Image: Dose distributions of photons and protons.  ER -